Abstracts tagged "severity"

Abstract Number: 430 • 2019 ACR/ARP Annual Meeting
Axial Spondyloarthritis Patients Report Important Impairments in Daily Life and Work Ability – a Web Survey in 472 Patients
Sebastian Ibanez¹, Rianne van Bentum ², Omar Valenzuela ³ and Irene van der Horst-Bruinsma ², ¹Facultad de Medicina Clinica Alemana - UDD, Santiago, Region Metropolitana, Chile, ²Amsterdam University Medical Center, Amsterdam, Netherlands, ³Facultad de Medicina Clinica Alemana -UDD, Santiago, Region Metropolitana, Chile
Background/Purpose: Axial spondyloarthritis (axSpA) can be associated with significant burden and impaired work activity. In Chile, several barriers impede adequate treatment, such as insufficient access…
Abstract Number: 1407 • 2017 ACR/ARHP Annual Meeting
Huntingtin Interactin Protein 1 (HIP1) Regulates Invasiveness, Actin Filament and Lamellipodia Formation in Rheumatoid Arthritis Fibroblast-like Synoviocytes (FLS)
Teresina Laragione, Carolyn Harris, Erjing Gao and Percio S. Gulko, Medicine/Rheumatology, Icahn School of Medicine at Mount Sinai, New York, NY
Background/Purpose: Huntingtin-interacting protein 1 (Hip1) is an arthritis severity and joint damage gene recently discovered in rodent models of arthritis. Hip1 regulates fibroblast-like synoviocytes (FLS)…
Abstract Number: 1408 • 2017 ACR/ARHP Annual Meeting
The Cation Channel TRPV2 Decreases Rheumatoid Arthritis Fibroblast-like Synoviocyte Invasiveness By Inhibiting RhoA Activation, Cell Adhesion and Actin Cytoskeleton Changes
Teresina Laragione, Carolyn Harris, Erjing Gao and Percio S. Gulko, Medicine/Rheumatology, Icahn School of Medicine at Mount Sinai, New York, NY
Background/Purpose: We have recently identified the non-selective cation channel TRPV2 (transient receptor potential vanilloid subfamily, type 2 channel) as a new central mediator of arthritis…
Abstract Number: 2602 • 2013 ACR/ARHP Annual Meeting
Reduced Frequencies Of Circulating CD8 T Cells In Early Diffuse Cutaneous Systemic Sclerosis Is Associated With Worse Skin Scores
Marie Hudson¹, Maximilien Lora², Christopher Di Ioia³, Solene Tatibouet⁴, Sasha Bernatsky⁵ and Ines Colmegna⁶, ¹Rheumatology, Lady David Institute for Medical Research and Jewish General Hospital, Montreal, QC, Canada, ²Rheumatology, McGill University Health Centre, Montréal, QC, Canada, ³McGill University, Montreal, QC, Canada, ⁴Jewish General Hospital, McGill University, Montreal, QC, Canada, ⁵Division of Clinical Epidemiology, McGill University Health Center, Montreal, QC, Canada, ⁶Rheumatology, McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: Diffuse cutaneous systemic sclerosis (dcSSc) is associated with significant morbidity and mortality. Measurement of skin thickness (modified Rodnan skin score (mRss)) is a surrogate…
Abstract Number: 354 • 2013 ACR/ARHP Annual Meeting
Disease Burden Among Patients With Psoriatic Arthritis Who Have Experienced First Line Tumor Necrosis Factor Inhibitor Regimen Failure In The European Union
Siva Narayanan¹, Yao Lu², Richard Hutchings² and Amanda Baskett², ¹Evidence Generation, Value and Access Center, Ipsos Healthcare, Columbia, MD, ²Ipsos Healthcare, London, United Kingdom
Background/Purpose: Data on second line biologic patients who have experienced 1st line tumor necrosis factor inhibitor (TNF) failure and associated disease burden among patients (pts)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].